| Phase 15 trials |
|
Phase 1
|
NCT07457229 |
Mar 2026 → May 2027 expected |
— |
GRIN Therapeutics, Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06975605 |
May → Jul 2025 |
isolated focal cortical dysplasia, tuberous sclerosis |
GRIN Therapeutics, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06965881 |
May → Jul 2025 |
isolated focal cortical dysplasia, tuberous sclerosis |
GRIN Therapeutics, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT05818943 |
Mar 2023 → Nov 2026 expected |
GRIN-related complex neurodevelopmental disorder |
GRIN Therapeutics, Inc. |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT02647697 |
Jan → Feb 2016 |
— |
UCB Biopharma S.P.R.L. |
Completed
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT06392009 |
Jul 2024 → Jun 2026 overdue |
isolated focal cortical dysplasia type II, tuberous sclerosis |
GRIN Therapeutics, Inc. |
Active not recruiting
|
No outcome recorded
|
| Phase 22 trials |
|
Phase 2
|
NCT02829827 |
Dec 2017 → Oct 2018 |
infantile spasms |
UCB Biopharma S.P.R.L. |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT00838799 |
Feb 2009 → Apr 2010 |
diabetic polyneuropathy |
Forest Laboratories |
Completed
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT07224581 |
Jan 2026 → May 2027 expected |
GRIN-related complex neurodevelopmental disorder |
GRIN Therapeutics, Inc. |
Recruiting
|
No outcome recorded
|